TLR4 and TLR7 agonists, including LPS and GS‐9620, have also been implicated in TLS neogenesis by enhancing CXCL13 expression and lymphoid aggregation in cancer and viral hepatitis models [111, 214]. This evidence concerns the gene CXCL13 and cancer.